S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
3 Free Stock Picks per Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Vatican singles out bishops in urging reflective not reactive social media use
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
3 Free Stock Picks per Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Vatican singles out bishops in urging reflective not reactive social media use
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
3 Free Stock Picks per Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Vatican singles out bishops in urging reflective not reactive social media use
S&P 500   4,205.45
DOW   33,093.34
QQQ   348.40
Stock market today: Markets mostly higher after Biden-McCarthy deal on US debt
The One Ticker Retirement Plan Over the Shoulder Demo Now Available (Ad)
Text released of 99-page bill to raise debt limit, curb spending; lawmakers to review as House eyes Wednesday vote
PwC Australia sidelines 9 directors as leak of tax information investigated
3 Free Stock Picks per Day (Ad)
North Korea notifies neighboring Japan it plans to launch satellite in coming days
Drought-struck Barcelona quenches thirst with costly desalination
3 Free Stock Picks per Day (Ad)
South African president appoints judge to oversee weapons-for-Russia inquiry
Vatican singles out bishops in urging reflective not reactive social media use
NASDAQ:LUMO

Lumos Pharma (LUMO) Earnings Date, Estimates & Call Transcripts

$3.77
+0.09 (+2.45%)
(As of 05/26/2023 03:50 PM ET)
Compare
Today's Range
$3.51
$3.81
50-Day Range
$3.01
$3.77
52-Week Range
$2.95
$9.56
Volume
20,300 shs
Average Volume
14,560 shs
Market Capitalization
$30.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.67

Earnings Summary

Upcoming
Earnings Date
Aug. 8Estimated
Actual EPS
(Mar. 1)
-$0.98 Missed By -$0.03
Consensus EPS
(Mar. 1)
-$0.95
Last Year's Q1 EPS
(3/10/2022)
-$0.68
Skip Charts & View Estimated and Actual Earnings Data

LUMO Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

LUMO Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Lumos Pharma Analyst Forecasts

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20234($1.16)($0.84)($1.05)
Q2 20234($1.18)($0.87)($1.03)
Q3 20234($1.21)($0.70)($1.03)
Q4 20234($1.12)($0.63)($0.84)
FY 202316($4.67)($3.04)($3.95)

LUMO Earnings Date and Information

Lumos Pharma last announced its quarterly earnings results on March 1st, 2023. The reported ($0.98) EPS for the quarter, missing analysts' consensus estimates of ($0.95) by $0.03. The company earned $0.51 million during the quarter, compared to analyst estimates of $0.34 million. Lumos Pharma has generated ($3.67) earnings per share over the last year (($3.67) diluted earnings per share). Earnings for Lumos Pharma are expected to grow in the coming year, from ($3.88) to ($2.96) per share. Lumos Pharma has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off prior year's report dates.

Lumos Pharma Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
8/8/2023
(Estimated)
        
3/1/2023Q4 2022($0.95)($0.98)($0.03)($0.98)$0.34 million$0.51 million
11/14/2022Q3 2022($1.01)($0.86)+$0.15($0.86)$0.40 million$0.50 million
8/9/2022Q2 2022($0.98)($0.94)+$0.04($0.94)$0.11 million$0.40 million
5/10/2022Q1 2022($0.92)($0.92)($0.92)$0.11 million
3/10/2022Q4 2021($0.92)($0.68)+$0.24($0.68)$0.22 million
11/3/2021Q3 2021($1.06)($0.90)+$0.16($0.90)
8/5/20216/30/2021($1.01)($1.04)($0.03)($1.04)$0.01 million    
5/5/20213/31/2021($0.85)($1.04)($0.19)($1.04)  
3/8/202112/31/2020($0.86)($0.31)+$0.55($0.31)$0.05 million$0.04 million  
11/10/20209/30/2020($0.65)$0.21+$0.86$0.21$7.80 million$0.07 million  
8/13/20206/30/2020($0.70)($0.6455)+$0.0545($0.65)$0.03 million  
5/28/2020Q1 2020($0.83)($0.14)+$0.69($0.14)$0.02 million  
2/28/2020Q4 2019($2.52)($1.98)+$0.54($1.98)$0.25 million$0.43 million
11/6/2019Q3 2019($2.43)($2.43)($1.35)$0.25 million
7/30/2019Q2 2019($2.61)($2.43)+$0.18($2.43)$0.15 million
5/8/2019Q1 2019($2.79)($2.43)+$0.36($2.43)$0.11 million
2/27/2019Q4 2018($3.06)($2.52)+$0.54($2.52)$0.38 million$0.20 million
11/1/2018Q3 2018($3.78)($1.80)+$1.98($1.80)$2.10 million$0.12 million
7/31/2018Q2 2018($5.31)($4.23)+$1.08($4.23)$5.85 million$2.25 million
5/3/2018Q1 2018($4.95)($4.41)+$0.54($4.41)$5.78 million$9.90 million
3/1/2018Q4 2017($6.21)($3.33)+$2.88($3.33)$2.72 million$10.10 million
11/2/2017Q3 2017($6.66)($6.21)+$0.45($6.21)$2.38 million$5.48 million
7/28/2017Q2 2017($7.11)($5.13)+$1.98($5.13)$2.65 million$10.37 million
5/4/2017Q1 2017($7.38)($6.48)+$0.90($6.48)$2.68 million$2.76 million
2/28/2017Q4 2016($5.94)($4.14)+$1.80($4.14)$4.31 million$12.70 million
11/1/2016Q3 2016($5.58)($4.86)+$0.72($4.86)$3.56 million$15.35 million
7/29/2016Q2 2016($7.02)($10.08)($3.06)($10.08)$4.81 million$2.01 million
4/29/2016Q1 2016($7.74)($7.38)+$0.36($7.38)$1.50 million$5.71 million
2/29/2016Q4 2015($7.56)($6.75)+$0.81($6.75)$4.85 million$7.65 million
11/3/2015Q3 2015($4.86)($4.95)($0.09)($4.95)$9.01 million$14.21 million
7/31/2015Q2 2015($5.76)($4.41)+$1.35($4.41)$5.60 million$7.45 million
5/5/2015Q1 2015($1.98)$3.15+$5.13$3.15$12.78 million$39.20 million
2/26/2015Q4 2014($7.02)$36.45+$43.47$36.45$3.88 million$3.30 million
11/6/2014Q3 2014($3.69)($1.80)+$1.89($1.80)$0.31 million$2.80 million
8/5/2014Q2 2014($3.78)($2.97)+$0.81($2.97)$0.30 million$0.21 million
5/6/2014Q1 2014($3.33)($2.97)+$0.36($2.97)$0.31 million$0.33 million
3/11/2014Q4 2013($3.33)($2.79)+$0.54($2.79)$0.33 million$0.29 million
11/12/2013Q3 2013($2.97)($2.88)+$0.09($2.88)$0.33 million$0.27 million
8/7/2013Q2 2013($2.97)($2.52)+$0.45($2.52)$0.38 million$0.23 million
5/6/2013Q1 2013($2.52)($2.97)($0.45)($2.97)$0.50 million$0.30 million












Lumos Pharma Earnings - Frequently Asked Questions

When is Lumos Pharma's earnings date?

Lumos Pharma has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, August 8th, 2023 based off last year's report dates. Learn more on LUMO's earnings history.

Did Lumos Pharma beat their earnings estimates last quarter?

In the previous quarter, Lumos Pharma (NASDAQ:LUMO) missed the analysts' consensus estimate of ($0.95) by $0.03 with a reported earnings per share (EPS) of ($0.98). Learn more on analysts' earnings estimate vs. LUMO's actual earnings.

How much revenue does Lumos Pharma generate each year?

Lumos Pharma (NASDAQ:LUMO) has a recorded annual revenue of $1.52 million.

How much profit does Lumos Pharma generate each year?

Lumos Pharma (NASDAQ:LUMO) has a recorded net income of -$31.06 million. LUMO has generated -$3.67 earnings per share over the last four quarters.

What is Lumos Pharma's EPS forecast for next year?

Lumos Pharma's earnings are expected to grow from ($3.88) per share to ($2.96) per share in the next year.

More Earnings Resources from MarketBeat

This page (NASDAQ:LUMO) was last updated on 5/29/2023 by MarketBeat.com Staff

My Account -